Sangamo Therapeutics (SGMOQ) Intangibles (2013 - 2023)

Sangamo Therapeutics' Intangibles history runs 8 years deep, the most recent figure standing at $51.6 million for Q1 2023.

• On a quarterly basis, Intangibles fell 2.13% year-over-year to $51.6 million in Q1 2023; TTM through Mar 2023 was $51.6 million, a 2.13% decrease from a year earlier, with the FY2022 full-year figure at $50.7 million, down 5.64% from the prior year.
• Intangibles climbed to $51.6 million in Q1 2023 per SGMOQ's latest filing, from $50.7 million in the prior quarter.
• Across five years, Intangibles topped out at $58.1 million in Q4 2020 and bottomed at $46.4 million in Q3 2022.
• The 5-year median for Intangibles is $53.2 million (2019), against an average of $53.1 million.
• Across the five-year window, Intangibles rose 9.35% in 2020 and slipped 15.45% in 2022, its largest moves.
• Year by year, Intangibles stood at $53.2 million in 2019, then rose by 9.35% to $58.1 million in 2020, then retreated by 7.51% to $53.8 million in 2021, then declined by 5.64% to $50.7 million in 2022, then gained by 1.63% to $51.6 million in 2023.
• Per Business Quant, the three latest SGMOQ Intangibles figures stand at $51.6 million (Q1 2023), $50.7 million (Q4 2022), and $46.4 million (Q3 2022).